Introducing the Microbiome into Precision Medicine

Trends in Pharmacological Sciences

Volumn 38, Issue 1, 2017, Pages 81-91

  Kuntz, Thomas M ^a,b   Gilbert, Jack A ^b,c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

^c ARGONNE NATIONAL LABORATORY   (United States)

^d MARINE BIOLOGICAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; PREBIOTIC AGENT; PROBIOTIC AGENT; RNA 16S;

BACTERIUM IDENTIFICATION; CELL COMMUNICATION; DNA POLYMORPHISM; DNA SEQUENCE; DYSBIOSIS; HUMAN; INTESTINE FLORA; MICROBIOME; NONHUMAN; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SOCIAL STATUS; XENOBIOTIC METABOLISM; MICROFLORA;

HUMANS; MICROBIOTA; PREBIOTICS; PRECISION MEDICINE; PROBIOTICS;

EID: 85005769346     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.001     Document Type: Review

References (107)

1. 1 Venter, J.C., et al. The sequence of the human genome. Science 291 (2001), 1304–1351.
2. 2 Guttmacher, A.E., et al. Genomic medicine – a primer. N. Engl. J. Med. 347 (2002), 1512–1520.
3. 3 McCarthy, J.J., et al. Genomic medicine: a decade of successes, challenges, and opportunities. Sci. Transl. Med., 5, 2013, 189sr4.
4. 4 Garraway, L.A., et al. Precision oncology: an overview. J. Clin. Oncol. 31 (2013), 1803–1805.
5. 5 Schork, N.J., Personalized medicine: Time for one-person trials. Nature 520 (2015), 609–611.
6. 6 Lederberg, J., Infectious history. Science 288 (2000), 287–293.
7. 7 Sender, R., et al. Are we really vastly outnumbered?. revisiting the ratio of bacterial to host cells in humans. Cell 164 (2016), 337–340.
8. 8 ElRakaiby, M., et al. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 18 (2014), 402–414.
9. 9 Surana, N.K., en Kasper, D.L., Deciphering the tete-a-tete between the microbiota and the immune system. J. Clin. Invest. 124 (2014), 4197–4203.
10. 10 Sampson, T.R., en Mazmanian, S.K., Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 17 (2015), 565–576.
11. 11 Dinan, T.G., et al. Collective unconscious: how gut microbes shape human behavior. J. Psychiatr. Res. 63 (2015), 1–9.
12. 12 Clarke, G., et al. Minireview: gut microbiota: the neglected endocrine organ. Mol. Endocrinol. 28 (2014), 1221–1238.
13. 13 Human genome at ten: the sequence explosion. Nature 464 (2010), 670–671.
14. 14 Franzosa, E.A., et al. Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. 112 (2015), E2930–E2938.
15. 15 David, L.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2013), 559–563.
16. 16 Gilbert, J.A., et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535 (2016), 94–103.
17. 17 Clarridge, J.E., en Alerts, C., Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin. Microbiol. Rev. 17 (2004), 840–862.
18. 18 Woo, P.C.Y., et al. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin. Microbiol. Infect. 14 (2008), 908–934.
19. 19 Galley, J.D., et al. Maternal obesity is associated with alterations in the gut microbiome in toddlers. PLoS One, 9, 2014, e113026.
20. 20 Sharpton, T.J., An introduction to the analysis of shotgun metagenomic data. Front. Plant Sci., 5, 2014, 209.
21. 21 Sangwan, N., et al. Differential functional constraints cause strain-level endemism in Polynucleobacter populations. mSystems 1 (2016), e00003–e00016.
22. 22 Cardona, C., et al. Network-based metabolic analysis and microbial community modeling. Curr. Opin. Microbiol. 31 (2016), 124–131.
23. 23 Thomas, T., et al. Metagenomics – a guide from sampling to data analysis. Microb. Inform. Exp., 2, 2012, 3.
24. 24 Jeffery, I.B., et al. Categorization of the gut microbiota: enterotypes or gradients?. Nat. Rev. Microbiol. 10 (2012), 591–592.
25. 25 Faust, K., et al. Metagenomics meets time series analysis: unraveling microbial community dynamics. Curr. Opin. Microbiol. 25 (2015), 56–66.
26. 26 Donaldson, G.P., et al. Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14 (2015), 20–32.
27. 27 Rowan, F., et al. Bacterial colonization of colonic crypt mucous gel and disease activity in ulcerative colitis. Ann. Surg. 252 (2010), 869–875.
28. 28 Kalow, W., en Genest, K., A method for the detection of atypical forms of human serum cholinesterase. determination of dibucaine numbers. Biochem. Cell Biol. 35 (1957), 339–346.
29. 29 Sultana, J., et al. Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother., 4, 2013, 73.
30. 30 Chan, A.L.F., et al. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: a prospective, descriptive, observational study. Curr. Ther. Res. 69 (2008), 118–129.
31. 31 Edwards, I.R., en Aronson, J.K., Adverse drug reactions: definitions, diagnosis, and management. Lancet 356 (2000), 1255–1259.
32. 32 Verbeurgt, P., et al. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 15 (2014), 655–665.
33. 33 Guengerich, F.P., Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21 (2008), 70–83.
34. 34 Sousa, T., et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363 (2008), 1–25.
35. 35 Rizkallah, R., M., et al. The PharmacoMicrobiomics portal: a database for drug–microbiome interactions. Curr. Pharmacogenomics Person. Med. 10 (2012), 195–203.
36. 36 Carmody, R.N., en Turnbaugh, P.J., Host–microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J. Clin. Invest. 124 (2014), 4173–4181.
37. 37 Wilson, I.D., Nicholson, J.K., The modulation of drug efficacy and toxicity by the gut microbiome. Molecular and Integrative Toxicology, 2015, Springer, 323–341.
38. 38 Rautio, J., et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008), 255–270.
39. 39 Watkins, P.B., et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 296 (2006), 87–93.
40. 40 Clayton, T.A., et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 14728–14733.
41. 41 Swanson, H.I., Drug metabolism by the host and gut microbiota: a partnership or rivalry?. Drug Metab. Dispos. 43 (2015), 1499–1504.
42. 42 Takasuna, K., et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56 (1996), 3752–3757.
43. 43 Haiser, H.J., en Turnbaugh, P.J., Developing a metagenomic view of xenobiotic metabolism. Pharmacol. Res. 69 (2013), 21–31.
44. 44 Shajib, M.S., en Khan, W.I., The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol. 213 (2015), 561–574.
45. 45 Viaud, S., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976.
46. 46 Davey, K.J., et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl. Psychiatry, 3, 2013, e309.
47. 47 Worsley, M.a., Infection control and prevention of Clostridium difficile infection. J Antimicrob Chemother 41:Suppl C (1998), 59–66.
48. 48 Rubinstein, E., en Camm, J., Cardiotoxicity of fluoroquinolones. J. Antimicrob. Chemother. 49 (2002), 593–596.
49. 49 Galatti, L., et al. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. Pharmacol. Res. 51 (2005), 211–216.
50. 50 Rubin, B.K., Tamaoki, J., (eds.) Antibiotics as Anti-Inflammatory and Immunomodulatory Agents, 2005, Birkhäuser-Verlag.
51. 51 Bailey, M.T., et al. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain. Behav. Immun. 25 (2011), 397–407.
52. 52 Wallace, B.D., en Redinbo, M.R., The human microbiome is a source of therapeutic drug targets. Curr. Opin. Chem. Biol. 17 (2013), 379–384.
53. 53 Maurice, C.F., et al. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152 (2013), 39–50.
54. 54 Eckert, R., et al. Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob. Agents Chemother. 50 (2006), 3651–3657.
55. 55 Guo, L., et al. Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 7569–7574.
56. 56 Belda-Ferre, P., et al. The human oral metaproteome reveals potential biomarkers for caries disease. Proteomics 15 (2015), 3497–3507.
57. 57 Wang, Z., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 (2015), 1585–1595.
58. 58 Yao, J., et al. A pathogen-selective antibiotic minimizes disturbance to the microbiome. Antimicrob. Agents Chemother., 2016 http://dx.doi.org/10.1128/AAC.00535-16 Published online May 9.
59. 59 Nobrega, F.L., et al. Revisiting phage therapy: new applications for old resources. Trends Microbiol. 23 (2015), 185–191.
60. 60 Kutter, E., et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11 (2010), 69–86.
61. 61 Summers, W.C., The strange history of phage therapy. Bacteriophage 2 (2012), 130–133.
62. 62 Koskella, B., en Meaden, S., understanding bacteriophage specificity in natural microbial communities. Viruses 5 (2013), 806–823.
63. 63 Petschow, B., et al. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann. N. Y. Acad. Sci. 1306 (2013), 1–17.
64. 64 Candela, M., et al. Functional intestinal microbiome, new frontiers in prebiotic design. Int. J. Food Microbiol. 140 (2010), 93–101.
65. 65 O'Keefe, S.J.D., et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun., 6, 2015, 6342.
66. 66 Preidis, G.A., en Versalovic, J., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136 (2009), 2015–2031.
67. 67 Garber, K., Drugging the gut microbiome. Nat. Biotechnol. 33 (2015), 228–231.
68. 68 Gerber, G.K., The dynamic microbiome. FEBS Lett. 588 (2014), 4131–4139.
69. 69 Gordon, S., Elie Metchnikoff: father of natural immunity. Eur. J. Immunol. 38 (2008), 3257–3264.
70. 70 Belda-Ferre, P., et al. The oral metagenome in health and disease. ISME J. 6 (2012), 46–56.
71. 71 Bron, P.a., et al. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 10 (2011), 66–78.
72. 72 Gavrish, E. et al. Google Patents. Devices and methods for the selective isolation of microorganisms.
73. 73 Strandwitz, P., et al. GABA-modulating bacteria: microbiome-based therapeutics for depression?. RISE, 2015.
74. 74 Amalaradjou, M.A.R., Bhunia, A.K., Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered 4 (2013), 379–387.
75. 75 Buffie, C.G., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2014), 205–208.
76. 76 Li, J., et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), E1306–E1315.
77. 77 Thompson, B.M., en Boiani, J., The legal environment for precision medicine. Clin. Pharmacol. Ther. 99 (2015), 167–169.
78. 78 Ginsburg, G.S., Realizing the opportunities of genomics in health care. JAMA 309 (2013), 1463–1464.
79. 79 Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership (2015) Plavix (package insert).
80. 80 Johnson, J.A., et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin. Pharmacol. Ther. 91 (2012), 774–776.
81. 81 van Nood Els, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368 (2013), 407–415.
82. 82 Manuck, S.B., en McCaffery, J.M., Gene–environment interaction. Annu. Rev. Psychol. 65 (2014), 41–70.
83. 83 Gauderman, W.J., Sample size requirements for matched case-control studies of gene–environment interaction. Stat. Med. 21 (2002), 35–50.
84. 84 Huang, Y.J., en Boushey, H.A., The microbiome in asthma. J. Allergy Clin. Immunol. 135 (2015), 25–30.
85. 85 Ellekilde, M., et al. Transfer of gut microbiota from lean and obese mice to antibiotic-treated mice. Sci. Rep. 4, 2014 http://dx.doi.org/10.1038/srep05922.
86. 86 Foster, J.A., McVey Neufeld, K.A., Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36 (2013), 305–312.
87. 87 Turnbaugh, P.J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
88. 88 Frank, D.N., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. 104 (2007), 13780–13785.
89. 89 Shah, P., et al. A microfluidics-based in vitro model of the gastrointestinal human–microbe interface. Nat. Commun., 7, 2016, 11535.
90. 90 Sun, X., et al. Patent watch: modulating the human microbiome with live biotherapeutic products: intellectual property landscape. Nat. Rev. Drug Discov. 15 (2016), 224–225.
91. 91 Morgan, B., Drug development: a healthy pipeline. Nature 533 (2016), S116–S117.
92. 92 Degnan, F.H., The US Food and Drug Administration and probiotics: regulatory categorization. Clin. Infect. Dis. 46 (2008), S133–S136.
93. 93 Lewis, Z.T., et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr. Res. 79 (2016), 445–452.
94. 94 Miller, G.E., et al. Lower neighborhood socioeconomic status associated with reduced diversity of the colonic microbiota in healthy adults. PLoS One, 11, 2016, e0148952.
95. 95 Rook, G.A.W., et al. Microbial “old friends”, immunoregulation and socioeconomic status. Clin. Exp. Immunol. 177 (2014), 1–12.
96. 96 Bailey, M.T., et al. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain. Behav. Immun. 25 (2011), 397–407.
97. 97 Block, J.P., et al. Fast food, race/ethnicity, and income: a geographic analysis. Am. J. Prev. Med. 27 (2004), 211–217.
98. 98 Powell, L.M., et al. Availability of physical activity–related facilities and neighborhood demographic and socioeconomic characteristics: a national study. Am. J. Public Health 96 (2006), 1676–1680.
99. 99 Almqvist, C., et al. Low socioeconomic status as a risk factor for asthma, rhinitis and sensitization at 4 years in a birth cohort. Clin. Exp. Allergy 35 (2005), 612–618.
100. 100 Bytzer, P., Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults. Gut 49 (2001), 66–72.
101. 101 McGuire, A.L., et al. Ethical, legal, and social considerations in conducting the Human Microbiome Project. Genome Res. 18 (2008), 1861–1864.
102. 102 Qureshi, N., en Kai, J., Genomic medicine for underserved minority populations in family medicine. Am. Fam. Physician 72 (2005), 386–387.
103. 103 Lynch, J.A., et al. Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet. Med. 15 (2013), 630–638.
104. 104 Adler, N.E., Socioeconomic inequalities in health. JAMA, 269, 1993, 3140.
105. 105 Penson, D.F., et al. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J. Clin. Epidemiol. 54 (2001), 350–358.
106. 106 Spatz, M., et al. Role of intestinal microorganisms in determining cycasin toxicity. Proc. Soc. Exp. Biol. Med. 124 (1967), 691–697.
107. 107 Schoeni, J.L., en Wong, A.C., Inhibition of Campylobacter jejuni colonization in chicks by defined competitive exclusion bacteria. Appl. Environ. Microbiol. 60 (1994), 1191–1197.